sentence: 19 As in other tumors , the occurrence of grade 2 – 4 skin toxicity in SCCHN patients treated with cetuximab has been associated with better outcome.15 ,17 Cetuximab appears to provide the greatest benefit for patients with oropharyngeal tumors , T1-3 tumors , concomitant boost , advanced nodal stage , high Karnofsky Performance scores , and for patients receiving treatment in the USA .